|
Synonyms: Cejemly® (China) | CS-1001 | CS1001 | WBP-3155 | WBP3155
sugemalimab is an approved drug (China (2021))
Compound class:
Antibody
Comment: Sugemalimab is a fully human, high-affinity anti-programmed death ligand 1 (PD-L1) IgG4 monoclonal antibody. It is a checkpoint inhibitor class immuno therapeutic. In vitro, it competitively blocks the binding of human PD-L1 to PD-1 and CD80, and it induces T lymphocyte proliferation and enhances antitumour immunity [2].
|
| No information available. |
Summary of Clinical Use  |
| Sugemalimab was issued its first clinical approval in China (December 2021) [1]. It is indicated as first-line treatment for EGFR gene mutation and anaplastic lymphoma kinase (ALK) negative metastatic non-small cell lung cancer (NSCLC). First-in-human safety, pharmacokinetics, preliminary efficacy for sugemalimab were reported in 2022 [2]. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT03312842 | A Phase Ia/Ib Study of CS1001 in Subjects With Advanced Solid Tumors | Phase 1 Interventional | CStone Pharmaceuticals | 2 | |
| NCT03728556 | A Study of CS1001 in Subjects With Stage III Non-Small Cell Lung Cancer | Phase 3 Interventional | CStone Pharmaceuticals | The GEMSTONE-301 study | 3 |
